Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:07:09.365Z.
Calculation as of: 2026-10-06T17:07:09.365Z.
Quote observation: 2026-10-06T17:04:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a1dfb6c252c1cf241c11dff63bdf10e98668db23039cc4017602387c5996572
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Genelux Corporation
Market Cap
$115.46M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Genelux Corporation (GNLX) | $115.46M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.34M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.48M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.76M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.82M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.05M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
